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A. Homology Modeling and Docking Studies
The human SIRT1 amino acid sequence was retrieved from the UniProt database (UniProt ID: Q96EB6) 1 and a 3D comparative model of the human SIRT1 enzyme was predicted by the PHYRE server using a yeast Sir2 X-ray crystal structure (PDB entry code: 2HJH, chain A) 2 as template. 2HJH showed high sequence identity with the target protein ( Fig. S1 ) and high Blast 3 and SAS 4 scores (Table S1 ).
Fig. S1
Sequence alignment between target SIRT1 and template Sir2 catalytic domain. 
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The binding site was defined on the C α of His363 for SIRT1 and C α of His187 for SIRT2, with a radius of 20 Å. Water molecules within the binding site definition of the SIRT2 protein were retained and considered in the docking studies, using the settings "toggle" and "spin".
For the ligand, the maximum degree of flexibility (fully flexible ligand) was adopted, and 10 docking runs were performed. The top-ranked poses were visually analysed with PyMOL. 7 The stereochemical quality of the protein structures was evaluated with the PROCHECK 8 tool: the Ramachandran plot for the SIRT1 homology model yielded 88.6% of residues in the "most favoured regions", 10.3% in "additional allowed regions", 1.1% in "generously allowed regions" and 0.0% in "disallowed regions", indicating a general high quality of the model (Fig. S2) . Institute, San Francisco, USA. Here, full length human SIRT2 cDNA was cloned into pHEX-2T with BamHI/EcoRI (original vector pGEX-2T from Phamacia in which the GST-encoding sequence was replaced by 6 x His). The resulting protein was an N-tagged 6 x His-Sirt2. We transformed pEV1440 into E. coli DH5α (Invitrogen) for plasmid purification and the purified plasmid was transformed into E. coli BL21 (DE3) for protein purification. First the protein was purified with affinity chromatography (Ni-NTA Superflow, Qiagen). In a second step the eluted protein was loaded on a PD10 desalting column (GE Healthcare) for buffer exchange.
The activity was determined and the active fractions were pooled. The enzyme was analyzed with SDS page. The IC50 with NA was determined and the activity with or without NAD + was tested.
SIRT1
Plasmid pTe34 (6961 bp) was provided from Prof. Dr. A. Salminen (University Kuopio, Finland). Here, a human SIRT1 ORF fragment was inserted into pGEX2T (Amersham). The resulting protein was an N-tagged GST-SIRT1 fusion protein. Transformations for plasmid or protein purification were performed like described for SIRT2. The protein was purified by using Glutathione Sepharose 4B Beads (Amersham Biosciences) for affinity chromatography.
Further purification and and analyses were performed like described before. 
C. Cellular Screens
SIRT inhibitors, EX-527, salermide and sirtinol were synthesized by us, while AK-7 was acquired from AKos GmbH. The inhibitors were dissolved in DMSO at a concentration of 20 mM for stock solutions and then appropriately diluted.
-Cell viability analysis
MCF-7 cells were incubated with growth media supplemented with DMSO or the indicated inhibitor at 30 µM for 0, 24, 48 and 72 hours. At each time point, cells were washed three times with PBS and once with EDTA, followed by trypsinisation. Cells were then suspended with PBS and cell numbers were determined using a haemocytometer. Representative data from three independent experiments are shown.
-Cell cycle analysis
Cell cycle analysis was performed by propidium iodide (PI) staining followed by FACS analysis. Both floating and adherent cells were harvested by trypsinisation, washed with PBS, fixed and permeablised with 90% cold ethanol. Cells were then stained with propidium iodide 
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N-tert-Butyl-5-trifluoroacetyl-10,11-dihydro-5H-dibenz[b,f]azepine-3-sulphonamide (19)
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1-(3-Nitro-10,11-dihydro-5H-dibenz[b,f]azepin-5-yl)-2,2,2-trifluoroethanone (21)
To a solution of 17 (200 mg, 0.69 mmol) in Ac 2 O (3 mL) was added at 0 ˚C HNO 3 (1 mL).
The resulting mixture was stirred at room temperature for 16 h, after which time the reaction was found to be complete (by TLC). The solution was poured dropwise onto crushed ice and the product extracted with EtOAc. The organic layer was washed with sat. NaHCO 3 (aq.), brine, dried over MgSO 4 , filtered and the solvent evaporated under reduced pressure to give a crude product (250 mg) which was used in the next step without purification. 241.0968. 
3-Nitro-10,11-dihydro-5H-dibenz[b,f]azepine (22)
10,11-Dihydro-5H-dibenz[b,f]azepine-5-carboxamide (26)
N
8-Cyano-10,11-dihydro-5H-dibenz[b,f]azepine-2-carboxamide (28)
